Erratum (DOI:10.1016/j.arcmed.2006.10.016);Gene Dosage Is Not Responsible for the Upregulation of MRP1 Gene Expression in Adult Leukemia Patients

Archives of Medical Research

Volumn 38, Issue 3, 2007, Pages 297-304

  Golalipour, Masoud ^a,b   Mahjoubi, Frouzandeh ^a   Sanati, Mohammad Hossein ^b  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Acute leukemia; Gene amplification; Multidrug resistance

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; UPREGULATION;

EID: 33847638457     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.06.001     Document Type: Erratum

References (34)

1. Sonneveld P. Multidrug resistance in haematological malignancies. J Int Med 247 (2000) 521-525
2. Liscovitch M., and Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5 (2002) 349-355
3. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., et al. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258 (1992) 1650-1654
4. Marie J.P., Zhou D.C., Gurbuxani S., Legrand O., and Zittoun R. MDR1/P-glycoprotein in hematological neoplasms. Eur J Cancer 32 (1996) 1034-1038
5. Cole S.P.C., and Deeley R.G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays 20 (1998) 931-935
6. Lockhart A.C., Tiorna R.G., and Kim B.R. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2 (2003) 685-698
7. Plasschaert S.L., de Bont E.S., Boezen M., vander Kolk D.M., Daenen S.M., Faber K.N., et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 15 (2005) 8661-8668
8. Schaich M., Soucek S., Thiede C., Ehninger G., and Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Hematol 128 (2005) 324-332
9. Duesberg P., Stindl R., and Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. PNAS 98 (2001) 11283-11288
10. Obara K., Ghazizadeh M., Shimizu H., Arai R., Tenjin T., Suzuki S., et al. Comparative genomic hybridization study of genetic changes associated with vindesine resistance in esophageal carcinoma. Int J Oncol 20 (2002) 255-260
11. Kuwano M., Uchiumi T., Hayakawa H., Ono M., Wada M., Izumi H., et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94 (2003) 9-14
12. Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A., et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64 (2004) 1403-1410
13. Nieth C., and Lage H. Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J Chemother 17 (2005) 215-223
14. Knutsen T., Mickley L., Ried T., Green E.D., du Manoir S., Schrock E., et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 23 (1998) 44-54
15. Zojer N., Dekan G., Ackermann J., Fiegl M., Kaufmann H., Drach J., and Huber H. Aneuploidy of chromosome 7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridization. Lung Cancer 28 (2000) 225-235
16. Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute nonlymphocytic leukaemias: biological and clinical implications. Br J Hematol 104 (1999) 328-335
17. Mahjoubi F., Hill R.J., and Peters G.B. Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer. Chromosome Res 14 (2006) 263-276
18. Ried T., Lengauer C., Cremer T., Wiegant J., Raap A.K., van der Ploeg M., et al. Specific metaphase and interphase detection of the breakpoint region in 8q24 of Burkitt lymphoma cells by triple color fluorescence in situ hybridization. Genes Chromosomes Cancer 4 (1992) 69-74
19. Mitelman F. ISCN An international system for human cytogenetic nomenclature: recommendations of the international standing committee on human cytogenetic nomenclature (1995), Karger, Basel, Switzerland
20. Duesberg P., Stindl R., and Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. PNAS 97 (2000) 14295-14300
21. Li R., Hehlman R., Sachs R., and Duesberg P. Chromosomal alterations cause the high rates and wide ranges of drug resistance in cancer cells. Cancer Genet Cytogenet 163 (2005) 44-56
22. Lupski J., and Stankiewicz P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genetics 1 (2005) 627-633
23. Knuutila S., Bjorkqvist A.M., Autio K., Tarkkanen M., Wolf M., Monni O., et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152 (1998) 1107-1123
24. Schwab M. Amplification of oncogenes in human cancer cells. Bioassays 20 (1998) 473-479
25. Zalcberg J., Hu X., Slater A., Parisot J., El-Osta S., Kantharidis P., et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 3 (2000) 66-75
26. Eijdems E.W., de Haas M., Coco-Martin J.M., Ottenheim C.P., Zaman G.J., Dauwerse H.G., et al. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 60 (1995) 676-684
27. Esteller M., Martinez-Palones J.M., Garcia A., Xercavins J., and Reventos J. High rate of MDR-1 and heterogeneous pattern of MRP expression without gene amplification in endometrial cancer. Int J Cancer 11 (1995) 798-803
28. Schneider E., Cowan K., Bader H., Toomey S., Schwartz G.N., Karp J.E., et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85 (1995) 186-193
29. Doubre H., Cesari D., Mairovitz A., Benac C., Chantot-Bastaraud S., Dagnon K., et al. Multidrug resistance-associated protein is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer 113 (2005) 568-574
30. Goldstein M., Rennert H., Bar-Shira A., Burstein Y., Yaron Y., and Orr-Urtreger A. Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors: amplification and overexpression of the multidrug resistance associated protein 1 gene (MRP1) in a metachronous tumor. Cancer Genet Cytogenet 141 (2003) 120-127
31. Kurz E.U., Cole S.P., and Deeley R.G. Identification of DNA-protein interactions in the 5′ flanking and 5′ untranslated regions of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-1 binding site. Biochem Biophys Res Commun 27 (2001) 981-990
32. Muredda M., Nunoya K., Burtch-Wright R., Kurz E., Cole P.C., and Deeley R. Cloning and characterization of the murine and rat mrp1 promoter regions. Mol Pharmacol 64 (2003) 1259-1269
33. Sullivan G., Yang J., Vassil A., Yang J., Bash-Babula J., and Hait W. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105 (2000) 1261-1267
34. Sukhai M., and Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharmacol Pharmaceut Sci 3 (2000) 268-280